XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details Textual) (USD $)
1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended
Dec. 23, 2003
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Common Stock [Member]
Mar. 31, 2014
Performance Shares [Member]
Dec. 31, 2013
Performance Shares [Member]
Mar. 31, 2014
Plan 2014 [Member]
Subsequent Event [Member]
Mar. 31, 2014
Restricted Stock [Member]
Dec. 31, 2010
Restricted Stock [Member]
Mar. 31, 2014
Restricted Stock Award [Member]
Mar. 31, 2013
Restricted Stock Award [Member]
Mar. 31, 2014
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock Issued During Period, Shares, Issued in Settlement for Termination of Certain Rights in Stock Purchase Agreement       152,241                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized             1,000,000         1,783,292
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant                       274,285
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                       10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares         366,126 907,336            
Allocated Share-based Compensation Expense   $ 1,045,387 $ 480,306   $ 836,000 $ 422,000            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights                 Ten percent of the issued restricted common stock vested on December31, 2011. The remaining ninety percent of the restricted shares were modified on January31, 2013 to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January31, 2014 and 50% on January31, 2015      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 5.21 $ 1.73           $ 5.75      
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award         the Company modified 907,336 existing time-vested and performance stock options by lowering the exercise price to $2.81. Additionally, the Company modified the vesting terms for its unvested performance stock options and unvested restricted stock to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January31, 2014 and 50% on January31, 2015              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period               0 112,720      
Class Of Warrant Or Right Issued 20,467                      
Class Of Warrant Or Right Exercise Price Of Warrants Issued $ 12.21                      
Class Of Warrant Or Right Amended Expiration Date Dec. 31, 2015                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning Balance           $ 2.81            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   31,500               31,500 234,137  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total   $ 812,000                    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition   11 months 23 days